The effects of nitroglycerin during cardiopulmonary resuscitation. 2014

Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
MSc Program Cardiopulmonary Resuscitation, University of Athens, Medical School, Greece, 75 Mikras Asias Street, 11527 Athens, Greece.

The outcome for both in-hospital and out-of hospital cardiac arrest remains dismal. Vasopressors are used to increase coronary perfusion pressure and thus facilitate return of spontaneous circulation during cardiopulmonary resuscitation. However, they are associated with a number of potential adverse effects and may decrease endocardial and cerebral organ blood flow. Nitroglycerin has a favourable haemodynamic profile which promotes forward blood flow. Several studies suggest that combined use of nitroglycerin with vasopressors during resuscitation, is associated with increased rates of resuscitation and improved post-resuscitation outcome. This article reviews the effects of nitroglycerin during cardiopulmonary resuscitation and postresuscitation period, as well as the beneficial outcomes of a combination regimen consisting of a vasopressor and a vasodilator, such as nitroglycerin.

UI MeSH Term Description Entries
D005996 Nitroglycerin A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives. Glyceryl Trinitrate,Anginine,Dynamite,Gilustenon,Nitrangin,Nitro-Bid,Nitro-Dur,Nitrocard,Nitroderm,Nitroderm TTS,Nitroglyn,Nitrol,Nitrolan,Nitrong,Nitrospan,Nitrostat,Perlinganit,Susadrin,Sustac,Sustak,Sustonit,Transderm Nitro,Tridil,Trinitrin,Trinitrolong,Nitro Bid,Nitro Dur,NitroBid,NitroDur,Trinitrate, Glyceryl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014662 Vasoconstrictor Agents Drugs used to cause constriction of the blood vessels. Vasoactive Agonist,Vasoactive Agonists,Vasoconstrictor,Vasoconstrictor Agent,Vasoconstrictor Drug,Vasopressor Agent,Vasopressor Agents,Vasoconstrictor Drugs,Vasoconstrictors,Agent, Vasoconstrictor,Agent, Vasopressor,Agents, Vasoconstrictor,Agents, Vasopressor,Agonist, Vasoactive,Agonists, Vasoactive,Drug, Vasoconstrictor,Drugs, Vasoconstrictor
D015427 Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. Ischemia-Reperfusion Injury,Injury, Ischemia-Reperfusion,Injury, Reperfusion,Reperfusion Damage,Damage, Reperfusion,Injury, Ischemia Reperfusion,Ischemia Reperfusion Injury,Ischemia-Reperfusion Injuries,Reperfusion Damages,Reperfusion Injuries
D016887 Cardiopulmonary Resuscitation The artificial substitution of heart and lung action as indicated for HEART ARREST resulting from electric shock, DROWNING, respiratory arrest, or other causes. The two major components of cardiopulmonary resuscitation are artificial ventilation (RESPIRATION, ARTIFICIAL) and closed-chest CARDIAC MASSAGE. Basic Cardiac Life Support,CPR,Code Blue,Mouth-to-Mouth Resuscitation,Cardio-Pulmonary Resuscitation,Life Support, Basic Cardiac,Cardio Pulmonary Resuscitation,Mouth to Mouth Resuscitation,Mouth-to-Mouth Resuscitations,Resuscitation, Cardio-Pulmonary,Resuscitation, Cardiopulmonary,Resuscitation, Mouth-to-Mouth,Resuscitations, Mouth-to-Mouth
D018696 Neuroprotective Agents Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective

Related Publications

Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
June 1984, The American journal of cardiology,
Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
July 1998, Resuscitation,
Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
January 2008, Resuscitation,
Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
March 2013, The American journal of emergency medicine,
Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
May 1977, JACEP,
Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
February 2006, The American journal of cardiology,
Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
August 2006, The American journal of cardiology,
Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
January 2000, Critical care medicine,
Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
November 1997, Resuscitation,
Antonia Stefaniotou, and Giolanda Varvarousi, and Dimitrios P Varvarousis, and Theodoros Xanthos
September 1992, European journal of anaesthesiology,
Copied contents to your clipboard!